{"filing":{"accession_number":"0001437749-26-026280","cik":"0000072444","ticker":"VXRT","company_name":"Vaxart, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"vxrt20260806_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/vxrt20260806_8k.htm"},"events":[{"id":25751,"run_id":23371,"accession_number":"0001437749-26-026280","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The 8-K discloses Vaxart's financial results for Q2 2026 via a press release (Exhibit 99.1) filed under Item 2.02 (Results of Operations and Financial Condition). The filing includes condensed consolidated balance sheets, statements of operations, revenue of $27.2M, net loss of $13.5M, and cash runway guidance into Q2 2027. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational performance.","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":26662,"accession_number":"0001437749-26-026280","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The 8-K discloses Vaxart's financial results for Q2 2026 via a press release (Exhibit 99.1) filed under Item 2.02 (Results of Operations and Financial Condition). The filing includes condensed consolidated balance sheets, statements of operations, revenue of $27.2M, net loss of $13.5M, and cash runway guidance into Q2 2027. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:05.325094+00:00","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-08-06"}]}